| Dr Aaron Kyle Graumann, MD | |
|
8600 Nicollet Ave S, Bloomington, MN 55420-2824 | |
| (605) 261-5044 | |
| Not Available |
| Full Name | Dr Aaron Kyle Graumann |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 14 Years |
| Location | 8600 Nicollet Ave S, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194042887 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 55632 (Minnesota) | Primary |
| 207R00000X | Internal Medicine | 55632 (Minnesota) | Secondary |
| 261Q00000X | Clinic/center | 55632 (Minnesota) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Park Nicollet Methodist Hospital | Saint louis park, MN | Hospice |
| Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
| Regions Hospital | Saint paul, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthpartners Medical Group | 1759293954 | 1430 |
News Archive
A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).
Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.
› Verified 1 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).
Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.
› Verified 1 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).
Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.
› Verified 1 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).
Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aaron Kyle Graumann, MD 8600 Nicollet Ave S, Bloomington, MN 55420-2824 Ph: (605) 261-5044 | Dr Aaron Kyle Graumann, MD 8600 Nicollet Ave S, Bloomington, MN 55420-2824 Ph: (605) 261-5044 |
News Archive
A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).
Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.
› Verified 1 days ago
Dr. Darren Dale Bray, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 8600 Nicollet Ave S, Bloomington, MN 55420 Phone: 952-541-2800 | |
Linda Eelkema, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7920 Old Cedar Ave S, Bloomington, MN 55425 Phone: 952-851-1000 Fax: 952-851-1092 | |
Aner Vlodaver, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 600 W 98th St, Bloomington, MN 55420 Phone: 952-885-6150 | |
Sandhya Joshi, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7920 Old Cedar Ave S, Bloomington, MN 55425 Phone: 952-428-1800 | |
Yasmin Jeanne Khan, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5320 Hyland Greens Dr, Bloomington, MN 55437 Phone: 952-993-2400 | |
Paul Albert Berry, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8600 Nicollet Ave S, Mail Stop 31500a, Bloomington, MN 55420 Phone: 952-887-6600 Fax: 952-886-7015 |